business / news / / NewsX
Sun Pharmaceutical Industries shares jumped over 6% in early trade and were trading at around ₹1,725 on both BSE and NSE at the time of writing.
Sun Pharma will acquire US-based Organon & Co. in an all-cash deal worth $11.75 billion.
KEY POINTS
- The deal will make Sun Pharma and Organon a combined entity operating in over 150 countries.
- Post-acquisition, at least 18 markets will generate over $100 million in annual revenue each.
- The deal boosts Sun Pharma's position in women’s health and biosimilars globally.
COMPANIES
Summarized by Newsio from NewsX. How we summarize →